tj202
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jan 28, 2019 (NCT03860038)
Timeline
Indications
Studied for
Mechanism of action
- Lymphocyte differentiation antigen CD38Supplementation
CD38 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03952091 | Phase 3 | Mar 27, 2019 | I-Mab Biopharma |
| NCT03860038 | Phase 2 | Jan 28, 2019 | Chinese Academy of Medical Sciences, I-Mab Biopharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| I-Mab Biopharma | For profit | 2 | 2 | 2 | 2019 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1